Ibuprofen B. Braun (Ibuprofen)

Ibuprofen blocks the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are required for prostaglandin production. By lowering prostaglandin levels, it diminishes pain signaling, reduces fever, and suppresses inflammatory swelling.

The specific dose and infusion rate are determined by the prescribing clinician based on the patient’s condition, weight, renal function, and therapeutic goals. Healthcare professionals should follow local guidelines and product labeling.

Safety data for intravenous ibuprofen during pregnancy are limited. It is generally avoided in the third trimester because of potential fetal risks. Breastfeeding mothers should consult a physician, as ibuprofen can be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Compared with other injectable NSAIDs such as ketorolac, ibuprofen offers a broader anti‑inflammatory profile and a slightly lower risk of renal toxicity at equivalent analgesic doses, but it may have a higher incidence of gastrointestinal upset. Choice depends on the clinical scenario and patient tolerance.

The product must be stored refrigerated between 2 °C and 8 °C, protected from light, and must not be frozen or shaken. Before use, inspect the vial for particulate matter and ensure the solution is at room temperature if required for infusion.

Ibuprofen B. Braun is given by intravenous infusion. The vial is typically diluted with compatible IV fluid according to the prescribing information, then infused over a specified period (often 15–30 minutes) under clinical supervision.

Serious risks include severe allergic reactions (anaphylaxis), gastrointestinal bleeding, acute kidney injury, cardiovascular events such as myocardial infarction or stroke, and rare skin reactions like Stevens‑Johnson syndrome. Prompt recognition and discontinuation are essential if these occur.

Contraindications include known hypersensitivity to ibuprofen or other NSAIDs, active gastrointestinal bleeding or ulcer disease, severe renal impairment, patients in the third trimester of pregnancy, and individuals receiving anticoagulant therapy with uncontrolled bleeding risk.